We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Renalytix Plc | RENX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 30.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 30.00 | 30.00 | 30.00 | 30.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 29/2/2024 08:51 by sandeep67 Ripe for big placing now that investors will be sucked in. |
Posted at 15/2/2024 14:56 by faz For those with no business experience posting here, or who have never managed an M&A operation. You dont make an offer on a business losing $38m a year by making them an offer equivalent to market cap. And you certainly dont do it if their sales are miniscule and have not grown in spite of FDA clearance. There is no business here and the market cap is a chimera. If a company thought they could turn this nonsense into a profit they certainly would not make an offer reflective of that profit nor its potential. There are no assets to strip this down to a lean mean cash cow; there is only bad management of a tiny niche product. A hype and a pension plan, but not for investors I suggest. |
Posted at 14/11/2023 11:20 by idomeneo "74tom - 15 Mar 2022 - 12:57:11 - 1692 of 2344 Renalytix - AI Solutions Transforming The Management Of Kidney Disease - RENXIdomeneo, your posts remind me of a troll on a football forum pretending to support a team when they actually hate them. What you are saying is akin to going on a Spurs forum and posting that you think Harry Kane will leave on a free transfer or that he's going to retire at 28 to focus on other opportunities. It's complete nonsense to suggest RENX will run out of money, just like it was nonsense to say that raising $50m will double the share count or that shorters are here because they think RENX is like Theranos. Nobody who was invested here would be talking such rubbish, so please quit with the 'we' and go find something else to troll!" This was at £2.50 6 months after the 50 day and the 200 day had rolled over, the company had repeatedly claimed x was going to happen and it subsequently didn't. This guy went on to attack Paul Scott who has been a successful investor analysing several hundred companies a year for over 20 years and has unearthed many multi-baggers over that time. You get the same people who latch onto a stock and attack anybody else with a different view. As an investor you should be interested in looking at all the negatives of your investment, ideally this would be a place where that happens, but it never has. Where somebody would say " you are wrong for these reasons...". NB I didn't mention Theranos because it was a fraud and not relevant here, so he wrongly inferred that. |
Posted at 06/11/2023 09:03 by ydderf No reflection here on the main story for investors, i.e. how could a market cap of nearly £1bn in May 2021, slip away to almost nothing now, with no comment on the phenomenonHere is what a typical shareholder here was thinking: wan22 Apr '21 - 06:28 - 1017 of 2336 Excellent news today, big in itself, as exemplified by the formation of a market access team focused on contracting with VA, DoD, and IHS facilities. It's only part of the initial stage of commercialisation, but wow, what a start! Not to mention the recognition and kudos in securing such an important contract. Very well done to the Renalytix team! |
Posted at 01/7/2023 17:06 by bertiebingo Added small amount. If cap raise is done over the weekend it could well move to another level before consolidating. Believe in the LT story and trying to pick a points to add are going to be tough. I didn't say it will collapse, just that others have (admittedly not all) notably Polarean where FDA was a false dawn for investors. |
Posted at 30/6/2023 12:55 by wan From the US market -Renalytix jumps 38% after FDA nod for lead product Jun. 30, 2023 7:24 AM Renalytix Plc (NASDAQ:RNLX) added ~38% in the pre-market Friday after the company said it received the FDA's De Novo marketing authorization for its lead product, KidneyIntelX.dkd, designed to assess the risk of kidney function decline in adults with type 2 diabetes and chronic kidney disease. Full story - The US market does not open until 2:30pm UK time, and Nasdaq is showing pre-market volume of over 2m shares already. Given the FDA news was delivered quite late yesterday, it will be interesting to see where US investors place Renalytix shares. |
Posted at 26/6/2023 07:41 by wan Just as an aside, some investors may have missed out from the first-order effects from AI (eg Nvidia etc). However, if we can work out where the cascading impact from the implementation of AI & ML will have significant and meaningful multi-year impact, then smaller investors could be well rewarded. In short, Renalytix, the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic for kidney disease, could be one such place, given the market size and need, for investors to benefit from 2nd-order and 3rd-order effects from AI & ML.From an AI in healthcare perspective, I would also include Verici Dx (VRCI). |
Posted at 19/5/2023 20:23 by 1jat Wan…..I am of a similar view…this GM is getting the house in order for a fund raise.We know one is needed (bar a miraculous explosion in paid for tests)… The price new funds can be raised at will largely be driven by the FDA opinion…. There is scope for the large investors with an inside track in the fund raise to dilute existing SH on disadvantageous terms….but that does guarantee the funds can be raised quickly and easily (assuming they are onboard). Now is a very risky time to add as rejection could be a fatal blow…..safer, but perhaps less rewarding to wait for the raise to be announced….and completed. |
Posted at 31/3/2023 09:12 by mr roper Interesting investor call.Fda response due in q2. CEO describes 2023 as "crossing the rubicon". Sinai switching to full commercial contract and seeing payments coming in from diversified sources. Tests were 1500 for last quarter, by q4 I'd hope that would be doubled to 3000. Exciting times |
Posted at 26/1/2023 14:26 by wan Given Renalytix intend to expand the indicated uses to include broader chronic kidney disease, health equity strategies and value based care, the following makes for an interesting read -After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023. By THOMAS ROSE AND HEATHER MOREHOUSE ETTINGER Jan 25, 2023 Focus on health equity and value-based care If there is one thing the pandemic has brought to the top of everyone’s mind, it’s how disparities in access to care and other social determinants of health can impact patient outcomes and health care costs. The market is also shifting to value-based models, with organizations moving toward a holistic, integrated approach to patient care. Investors are seeing the benefits of pursuing health equity and quality, which can ultimately reduce costs, mitigate risk, and improve patient outcomes. Life sciences companies are also shifting to a diversity mindset for R&D. For example, recent developments in mental health treatments, such as those targeting post-pardum depression and schizophrenia, are filling gaps in care for previously marginalized groups. Going into 2023, M&A may begin to shift to those organizations championing quality and equity strategies that align with investor objectives. Strategic collaborations may be another viable option for organizations pursuing innovative new models and care integration. Health sciences companies and acquirers will also need to consider how value-based care models might impact financial risk and marketability of a product or service as they evaluate deal potential. Full article - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
